The QualityStocks Daily Wednesday, April 19th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(LUNRW) $0.6300 +79.95%

QualityStocks(CJJD) $1.1100 +64.44%

PennyStockProphet(VYNE) $4.4600 +42.49%

The QualityStocks Daily Stock List

China Jo-Jo Drug Stores (CJJD)

QualityStocks, MarketBeat, SmallCapVoice, BUYINS.NET, StocksEarning, The Street, StreetInsider, StockOodles, PennyStockLocks.com, ResearchOTC, StockRockandRoll, The Online Investor, Wall Street Resources, Street Insider, PennyTrader Publisher, The Weekly Options Trader, Penny Stock Rumble, Money Wealth Matters, MarketClub Analysis, TradersPro, INO.com Market Report, INO Market Report and StockMarketWatch reported earlier on China Jo-Jo Drug Stores (CJJD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

China Jo-Jo Drugstores Inc. (NASDAQ: CJJD) (FRA: 04CN) is engaged in the distribution and retail of pharmaceutical products as well as other healthcare products in China.

The firm has its headquarters in Hangzhou, the People’s Republic of China and was incorporated in 2006, on December 19th by Li Qi and Lei Liu. It operates in the consumer staples sector, under the retail and wholesale industry. The firm serves consumers in China.

The enterprise operates through the following segments: herb farming, drug wholesale, online pharmacy and retail drugstores. The farming segment grows various herbs which are sold to other drug vendors while the wholesale segment is engaged in the supply of the enterprise’s drug stores with medications, sundry items and medical devices. Additionally, the drugstores segment is involved in the sale of medical devices, family and personal care products, traditional Chinese medicine, nutritional supplements, over-the-counter and prescription medications and convenience products which include promotional, seasonal and consumable items. The online pharmacy is involved in the sale of nutritional supplements and other products via 3rd party platforms like Amazon.com and JD.com as well as its own platform, called dada360.com.

As of March 31, 2020, the company had 10 pharmacies and over 115 retail pharmacies under the Jiuzhou Grand Pharmacy name. The firm received the CHEO Award from the China Health Ecology Organization in September 2020, which is a health industry conference that has great influence and high standards. This award helps boost confidence in the firm, which is actively striving to promote their smart medicine diagnosis model.

China Jo-Jo Drug Stores (CJJD), closed Wednesday's trading session at $1.11, up 64.4444%, on 120,833,141 volume. The average volume for the last 3 months is 304,889 and the stock's 52-week low/high is $0.61/$9.6499.

InVivo Therapeutics (NVIV)

QualityStocks, OurHotStockPicks, Real Pennies, Xtremepicks, TraderPower, StockMarketWatch, TheStockAdvisor, MadPennyStocks, PennyInvest, StockEgg, SmallCapVoice, HotOTC, StockRich, CoolPennyStocks, BUYINS.NET, BullRally, PennyStockVille, MarketBeat, OTC Stock Review, SmallCap Fortunes, Marketbeat.com, TheMicrocapNews, NYC Marketing Inc, MarketClub Analysis, M2 Communications, InvestorPlace, INO Market Report, Buzz Stocks, InvestmentHouse, SECFilings.com News, TheStockAdvisors, The Street, The Stock Dork, Streetwise Reports, StockOodles, PennyStockScholar, Stock Market Watch, OTCtipReporter, Schaeffer's, TopPennyStockMovers, Top Pros' Top Picks, Barchart, PennyTrader Publisher, Weekly Wizards and StockEarnings reported earlier on InVivo Therapeutics (NVIV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) (FRA: 04IC) is a clinical-stage research and biotechnology firm that is focused on the development and commercialization of biopolymer scaffolding devices which are used to treat spinal cord injuries.

The firm is based in Cambridge, Massachusetts and was incorporated in January 2005 by Robert Langer, Frank M. Reynolds and Joseph P. Vacanti. It operates in the healthcare sector, under the medical equipment and devices sub-industry.

The company’s objective is to change the treatment of spinal cord injuries by modulating the healing environment to facilitate cell growth and survival. Currently, it is focused on using polymers as a platform technology to develop therapies that will enhance function in patients who experienced traumatic spinal cord injuries and got paralyzed as a result.

The enterprise’s pipeline comprises of an investigational bio-resorbable polymer scaffold developed for implantation at the injured site in a spinal cord, known as a Neuro-Spinal Scaffold implant. The scaffold has been designed to encourage functional cells to fill in the cavity that develops at the injury site in a spinal cord. Its success has the potential to improve motor and sensory function, leading to a better quality of life for patients.

The U.S. FDA recently announced its acceptance of the firm’s preclinical module, which brings them one step closer to complete HDE submission. The firm is now enrolling acute spinal cord injury patients into its INSPIRE 2 study which has been designed to expand upon clinical evidence of its spinal scaffold implant from its INSPIRE 1 study. Final approval from the FDA for its neuro-spinal scaffold implant will not only allow the company to help patients with spinal cord injuries but also bring in more investments into the firm, which will boost the company’s growth.

InVivo Therapeutics (NVIV), closed Wednesday's trading session at $1.39, up 12.0968%, on 304,889 volume. The average volume for the last 3 months is 103,579 and the stock's 52-week low/high is $0.806/$13.7699.

Evoke Pharma (EVOK)

MarketBeat, Kiplinger Today, Jason Bond, TradersPro, BUYINS.NET, StockMarketWatch, Marketbeat.com, QualityStocks, Daily Trade Alert, StreetInsider, Streetwise Reports, TopPennyStockMovers, TraderPower, Penny Stock Prodigy, StockEarnings, Investing Futures, Money Wealth Matters, Barchart, Seeking Alpha, Trades Of The Day, Short Term Wealth, Stock Market Watch, Street Insider and Schaeffer's reported earlier on Evoke Pharma (EVOK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Evoke Pharma Inc. (NASDAQ: EVOK) (FRA: EV0) is a pharmaceutical firm that is engaged in the manufacture, development and commercialization of therapies that can treat gastroenterological ailments and disorders.

The firm has its headquarters in Solana Beach, California and was incorporated in January 2007 by David A. Gonyer, Scott L. Glenn, Cam L. Garner and Matthew J. D’Onofrio. The firm serves consumers in the United States.

The enterprise markets its products to select health care providers, primary care physicians, internal medicine specialists and gastroenterologists. Its product pipeline is made up of a metoclopramide nasal spray known as Gimoti, which has concluded phase 3 clinical trials testing its effectiveness in treating symptoms linked to recurrent and acute diabetic gastroparesis in females. This gastrointestinal disorder hinders the stomach from emptying its contents at the appropriate time, which results in severe digestive system symptoms. It affects millions globally. The spray formulation, which is a mixed 5-HT3 and 5-HT4 antagonist, has anti-emetic and promotility effects and has been designed to offer systemic delivery of the molecule via the nasal mucosa. Before this formulation was developed, metoclopramide was the sole drug available in the U.S. indicated for the treatment of gastroparesis. The drug was only available in intravenous and oral forms.

The company recently announced its financial results for 2021’s second quarter, with its CEO noting that they were focused on driving the company’s marketing and commercial initiatives forward and making Gimoti the preferred treatment option for diabetic gastroparesis patients, which would not only bring in investment opportunities into the firm but also extend its consumer reach, which would be good for the company’s growth.

Evoke Pharma (EVOK), closed Wednesday's trading session at $2.1, up 10.5263%, on 103,579 volume. The average volume for the last 3 months is 270,364 and the stock's 52-week low/high is $1.3717/$16.80.

NextPlay Technologies (NXTP)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat and Early Bird reported earlier on NextPlay Technologies (NXTP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NextPlay Technologies Inc. (NASDAQ: NXTP) (FRA: 6NI) is a technology solution firm that is focused on the provision of connected TV, crypto-banking, in-game advertising, games and booking services for travel within an evolving global digital ecosystem.

The firm has its headquarters in Sunrise, Florida. Prior to its name change, the firm was known as Monaker Group Inc. The company changed its name after acquiring HotPlay Enterprise Ltd, a provider of online to offline couponing solutions and AI-powered, in-game advertising technology with hyper-local insertion capability. The firm serves consumers around the globe, with a focus on the United States.

The enterprise is focused on consumer-engaging products in the travel and video gaming verticals, with Blockchain, AI and Advertising technology solutions. The enterprise’s objective is to build a next-generation firm via organic growth and acquisitions. It plans to leverage the channels and strengths of its existing channels with those of the firms it acquires, which will help create opportunity as well as synergy in the leisure space.

The HotPlay Enterprise acquisition helped expand the firm’s already growing digital ecosystem, which includes Digital Connected TV that has a reach of over 50 million end-users. The company is now focused on leveraging the synergies among its digital platforms to take advantage of the various opportunities for growth and expansion ahead. Using its powerful digital platform to connect brands and firms with consumers across various interactive media channels will not only help extend the company’s consumer reach but also bring in more investors into the firm.

NextPlay Technologies (NXTP), closed Wednesday's trading session at $1.88, up 13.1167%, on 270,364 volume. The average volume for the last 3 months is 13.957M and the stock's 52-week low/high is $0.9301/$10.98.

Petros Pharmaceuticals (PTPI)

MarketClub Analysis, QualityStocks, Trades Of The Day and The Online Investor reported earlier on Petros Pharmaceuticals (PTPI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Petros Pharmaceuticals Inc. (NASDAQ: PTPI) is a pharmaceutical firm that is focused on the acquisition, development and commercialization of therapeutics for men’s health issues.

The firm has its headquarters in New York and was incorporated in 2020, on May 14th. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm serves consumers around the globe.

The company is focused on therapies which promote the preservation, tolerability and medication adherence of male organic function as an interdependent and integrated spectrum. It operates via its medical devices, and the prescription medications segments. The devices segment is comprised of vacuum erection devices while the prescription segment handles the company’s patented formulations.

The enterprise’s product portfolio is comprised of its new and patented topical candidate dubbed H100, which has been developed to treat acute Peyronie’s disease. The enterprise also develops its PDE-5 inhibitor prescription drug known as Stendra, which has been developed to treat erectile dysfunction. Stendra is the sole patent-protected PDE-5 inhibitor on the market which has been approved by the FDA for use. The enterprise markets its line of vacuum erection device products through Timm Medical Inc., its subsidiary.

The firm recently implemented a strategic change to its distribution model which will enhance process efficiencies and improve the firm’s ability to meet market demand with even greater accuracy. It is currently focused on expanding access to its Stendra product in order to reach more men who seek treatment for erectile dysfunction.

Petros Pharmaceuticals (PTPI), closed Wednesday's trading session at $6.55, up 19.0909%, on 13,957,093 volume. The average volume for the last 3 months is 111,531 and the stock's 52-week low/high is $0.9172/$28.80.

Acumen Pharmaceuticals (ABOS)

MarketBeat, QualityStocks, MarketClub Analysis, INO Market Report, Trades Of The Day and Daily Trade Alert reported earlier on Acumen Pharmaceuticals (ABOS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical firm that is focused on developing therapeutics to treat various neurodegenerative illnesses.

The firm has its headquarters in Charlottesville, Virginia and was incorporated in 1996, by Caleb Finch, Grant A. Krafft and William L. Klein. The firm serves consumers around the globe.

The company leverages decades of research to deliver targeted treatments which can impact patients afflicted by Alzheimer’s disease, which currently has no cure. It is developing a new illness-modifying approach which targeted a major underlying cause of Alzheimer’s.

The enterprise is advancing a therapeutic candidate known as ACU193, which it believes possesses disease-modifying benefits and offers symptomatic benefits for patients with Alzheimer’s disease. Amyloid-beta oligomers are a pathogenic and toxic form of Ab relative to amyloid plaques and AB monomers. This immunotherapy candidate has been developed to target amyloid-beta oligomers, which are a persistent driver of the neurodegeneration and pathology associated with Alzheimer’s. The humanized monoclonal antibody candidate is undergoing a phase 1 clinical trial evaluating its tolerability and safety, as well as its target engagement and pharmacokinetics. Thus far, the candidate has demonstrated in-vivo pharmacologic activity and safety in multiple animal species, including transgenic models for Alzheimer’s disease.

The firm is focused on completing its ACU193 phase 1 clinical trial. It is currently screening and enrolling patients for this trial, dubbed INTERCEPT-AD. Positive results bring this candidate one step closer to approval for use by Alzheimer’s patients, which will not only benefit patients with this indication but also encourage more investments into the firm.

Acumen Pharmaceuticals (ABOS), closed Wednesday's trading session at $4, up 11.4206%, on 112,061 volume. The average volume for the last 3 months is 10,377 and the stock's 52-week low/high is $3.02/$10.97.

YanGuFang International (YGF)

We reported earlier on YanGuFang International (YGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

YanGuFang International Group Co. Ltd (NASDAQ: YGF) is a holding firm that is focused on the research and development, production and sale of grain and oat products.

The firm has its headquarters in Shanghai. China and was incorporated in 2020. It operates as part of the packaged foods industry, under the consumer defensive sector. The firm serves consumers around the globe, with a primary focus on those in the People’s Republic of China.

The company provides oat germ groats, oat bran, oat flour, oatmeal and gourmet rice; and grains, including red beans, black beans, corn and other grains. The company also offers oat nutrient and health series products comprising oat peptide series products, oat ß-glucan probiotics, dietary fiber powder, flaxseed oil, oat biscuits and perilla seed oil series products, as well as oat daily necessity series, such as oat toothpaste, oat face cleanser, oat face mask, oat hand soap, and hand cream products. In addition, it provides technology consulting and related services. The company sells its products through its own sales team and distribution network, as well as offline and online channels. It mainly distributes its products in the domestic market and overseas markets.

The enterprise, which recently launched its IPO, is focused on construction of additional production facilities, marketing and brand promotion, research and development of new products and technologies and global business expansion. This will not only increase supply and extend its consumer reach but also help create value for its shareholders.

YanGuFang International (YGF), closed Wednesday's trading session at $3.32, off by 4.3228%, on 10,410 volume. The average volume for the last 3 months is 3,501 and the stock's 52-week low/high is $3.005/$4.01.

180 Degree Capital (TURN)

StockRockandRoll, PennyStockLocks, Penny Stock 101, MarketBeat, QualityStocks, InvestorPlace and InsiderTrades reported earlier on 180 Degree Capital (TURN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

180 Degree Capital Corp (NASDAQ: TURN) is a non-diversified closed-end management investment firm that is focused on investing in and providing value-added assistance through constructive activism.

The firm has its headquarters in Montclair, New Jersey and was incorporated in 1981. Prior to its name change, the firm was known as Harris & Harries Group Inc. It operates as part of the asset management industry, under the financial services sector. The firm primarily serves consumers in the United States.

The company’s investment objective is to generate capital appreciation and current income from investments and investment-related activities such as managed funds and accounts. It invests its assets in a range of industries, including advertising, asset management and custody banks, application software, biotechnology, construction machinery and heavy trucks, communications equipment, electronic manufacturing services, health care equipment, fertilizers and agricultural chemicals, health care technology, pharmaceuticals, interactive media and services, restaurants, specialty chemicals, specialized finance, technology hardware, trading companies and distributors, storage and peripherals, miscellaneous common stocks industries, steel and apparel, accessories and luxury goods.

The enterprise primarily provides portfolio management for pooled investment vehicles, and pension consulting services. It manages separate client-focused equity and balanced funds. It invests in exchange-traded equity securities, non exchange-traded equity securities, cash and cash equivalents and assets of the adviser that are primarily receivables and prepaid expenses. The firm conducts in-house research to make investments.

The firm, which recently gave a corporate update, remains committed to generating value for its shareholders.

180 Degree Capital (TURN), closed Wednesday's trading session at $4.9319, off by 0.965863%, on 3,502 volume. The average volume for the last 3 months is 673,794 and the stock's 52-week low/high is $4.85/$6.68.

Granite Point Mortgage Trust (GPMT)

MarketBeat, The Online Investor, StreetInsider, StockMarketWatch, Wealth Insider Alert, Investors Alley, The Street, Schaeffer's, QualityStocks and Daily Market Beat reported earlier on Granite Point Mortgage Trust (GPMT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Granite Point Mortgage Trust Inc. (NYSE: GPMT) (FRA: G18) is a real estate investment trust that is focused on originating, investing in and managing senior floating-rate commercial mortgage loans and other debt and debt-like commercial real estate investments.

The firm has its headquarters in New York, the United States and was incorporated in 2017, on April 7th. It operates as part of the REIT-Mortgage industry, under the real estate sector. The firm serves consumers in the United States.

The company’s investment objective is to preserve its stockholder's capital while generating attractive risk-adjusted returns over the long term, primarily through dividends derived from current income produced by its investment portfolio. It constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available on the market. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders.

The enterprise provides intermediate-term bridge or transitional financing for different purposes, including acquisitions, refinancing and recapitalizations, as well as a range of business plans, including lease-up, renovation, repositioning, and repurposing of the commercial property.

The firm, which recently announced its latest financial results, remains committed to managing its business in a conservative manner and generating value for its shareholders, which will greatly bolster overall growth.

Granite Point Mortgage Trust (GPMT), closed Wednesday's trading session at $4.6, off by 0.647948%, on 873,113 volume. The average volume for the last 3 months is 184,262 and the stock's 52-week low/high is $4.48/$11.15.

KNOT Offshore Partners (KNOP)

The Online Investor, MarketBeat, Zacks, StreetInsider, RedChip, Trading Concepts, Daily Trade Alert, StreetAuthority Daily, InvestorPlace, StockMarketWatch, FreeRealTime, Investing Daily, Investiv, BUYINS.NET, Short Term Wealth, Stocks To Watch, StocksEarning, The Street, Top Pros' Top Picks and Schaeffer's reported earlier on KNOT Offshore Partners (KNOP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

KNOT Offshore Partners LP (NYSE: KNOP) is a limited partnership company focused on owning, acquiring and operating shuttle tankers under long-term charters in Brazil and the North Sea.

The firm has its headquarters in Aberdeen, the United Kingdom and was incorporated in 2013, on February 21st. It operates as part of the marine shipping industry, under the industrials sector. The firm serves consumers around the globe.

The enterprise’s fleet are chartered to Transpetro, Equinor, Shell, Repsol, Var, ENI, Galp, KNOT and PetroChina. Its tankers are all equipped with the latest advanced technology, including dynamic positioning and offshore systems, ensuring safe and efficient offloading from offshore installations in the most challenging of locations and weather conditions. Its charters have an average remaining term of two years. The customers hire the enterprise's vessels for loading, transportation, discharge, and storage of their crude oil using the vessels in its fleet. It offers all these services under time charters and bareboat charters. The company has a fleet of over 17 shuttle tankers, which are vessels designed to transport crude oil and condensates from offshore oil field installations to onshore terminals and refineries. Its shuttle tankers include Recife Knutsen, Fortaleza Knutsen, Bodil Knutsen, Carmen Knutsen, Windsor Knutsen, Hilda Knutsen, Dan Cisne, Torill Knutsen, Dan Sabia, Raquel Knutsen, Ingrid Knutsen, Tordis Knutsen, Vigdis Knutsen, Tove Knutsen, Lena Knutsen, Anna Knutsen and Brasil Knutsen.

The company remains focused on entering into more long-term charters to generate additional revenues and create shareholder value.

KNOT Offshore Partners (KNOP), closed Wednesday's trading session at $5.03, up 0.199203%, on 258,075 volume. The average volume for the last 3 months is 1.207M and the stock's 52-week low/high is $4.72/$18.85.

YS Biopharma (YS)

We reported earlier on YS Biopharma (YS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

YS Biopharma Co. Ltd (NASDAQ: YS) is a biopharmaceutical firm that is focused on the discovery, development, manufacture and commercialization of vaccines and therapeutic biologics for infectious illnesses and cancer.

The firm has its headquarters in Beijing, China and was incorporated in 2022. Prior to its name change, the firm was known as Summit Healthcare Acquisition Corp. It operates as part of the biotechnology industry, under the healthcare sector. The firm operates in the United States, the United Arab Emirates, the Philippines, China and Singapore. It primarily serves consumers in the People’s Republic of China.

The company has over 800 employees and is led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry.

The enterprise has developed a PIKA immunomodulating technology platform, which include 4 clinical stage candidates, targeting a wide range of clinical indications with significant market potential, like rabies, hepatitis B, coronavirus, shingles and influenza, among other indications. It is also involved in the production and sale of YSJA, a rabies vaccine and the first aluminum-free lyophilized rabies vaccine that was launched in China.

The company recently entered into a definitive agreement for a business combination of Summit and YS Biopharma. This move will fuel its strategy for future business expansion and execution and allow shareholders to participate in the significant upside potential created by the partnership. This is in addition to bolstering the company’s overall growth.

YS Biopharma (YS), closed Wednesday's trading session at $1.73, up 8.125%, on 1,206,752 volume. The average volume for the last 3 months is 24.106M and the stock's 52-week low/high is $1.32/$18.4399.

Nikola Corporation (NKLA)

Green Car Stocks, Schaeffer's, InvestorPlace, QualityStocks, MarketClub Analysis, StocksEarning, MarketBeat, The Street, Kiplinger Today, StockEarnings, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, Early Bird, Zacks, Cabot Wealth, Louis Navellier, CNBC Breaking News, Investopedia, Wealth Insider Alert, MarketTamer, Daily Profit, GreenCarStocks, Outsider Club, StockMarketWatch, AllPennyStocks and Green Energy Stocks reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Volkswagen says that for all its electric cars, it is developing a new, more powerful, and effective engine and drive framework. It claims that thanks to increased efficiency, its new APP 550 propulsion system will enhance the performance of batteries in rear-wheel drive vehicles as well as increase their range. According to Volkswagen, by the end of this year, the first vehicles with the modern 210 kW/280 horsepower electric drive framework will be delivered.

The MEB platform, which is the foundation for all company-branded ID vehicles, will continue to be used as the design base for this new drive system, Karsten Bennewitz stated in a press release issued by the company. Bennewitz claimed that they had to build a new drive, which was capable of significantly improving efficiency and performance despite the constraints imposed on them by each other.

Besides greater performance, the APP 550’s powertrain also has more torque based on the gear ratio of the vehicle, with up to 550 Nm405 lbft of torque. With an increased stator with a higher number of usable windings and wider wire cross sections, the significant increase in torque is capable of providing great power at both low speeds and at higher speeds. The rotor has strong magnetic materials installed in it, increasing its load capability. In order to cope with the increased torque, the drive has been strengthened as well.

The more powerful and efficient inverter that has recently been designed can provide the increased electrical current required by a propulsion system whose working software makes sure the system runs effectively. This implies that in different load scenarios, the timing and modulation techniques used to generate asynchronous current for an electric motor are capable of making it work more effectively.

It gets hotter as the power and current increase. Volkswagen has improved a range of components within the power train, such as the temperature regulation system, with a view to increasing electric drive efficiency. The APP 550 is equipped with a cooling system that uses less energy and does not use an electric oil pump. Because of the gear wheels in the gearbox, as well as specially designed components that are used to deliver and distribute oil, the engine’s cooling circuit can mop up heat from the drive system. On the outside of the stator, a heat sink that uses water cooling is mounted.

Volkswagen’s components facility in Kassel, Germany, will produce the drive system composed of a gear box, stator and rotor. In the world of EVs, this is interesting news. The latest technologies are being launched regularly, and drivers who need basic transport rather than larger tour buses are also being taken into account.

The EV industry is evolving rapidly, and one can only expect that as time goes by, other industry players such as Nikola Corporation (NASDAQ: NKLA) will also introduce their own innovations aimed at giving their offerings a competitive edge on the market.

Nikola Corporation (NKLA), closed Wednesday's trading session at $0.91, off by 6.953%, on 24,425,685 volume. The average volume for the last 3 months is 119,554 and the stock's 52-week low/high is $0.8111/$8.97.

The QualityStocks Company Corner

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, was featuredin an equity research report published by Aegis Capital Corp. Inthe report, Aegis Capital maintained a buy rating for BVXV at a $70target price. The publication reads, “R&D expenses for 2022 of$5.8 million were in-line with our expectations and G&Aexpenses were a bit higher than estimated at $5.3 million. Webelieve R&D expenses could rise to $7 million in 2023 as thecompany licenses additional NanoAb candidates and assuming that aPhase 1/2a clinical trial for the anti-COVID-19 NanoAb begins thisyear. We expect G&A expenses to remain stable.”

To request access to the full report, visit https://ibn.fm/mD1Dv

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Wednesday's trading session at $2.14, up 9.7436%, on 119,624 volume. The average volume for the last 3 months is 1.185M and the stock's 52-week low/high is $1.70/$17.60.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services, andthe only provider building both annealing and gate-model quantumcomputers, has published a peer-reviewed milestone paper showingthe performance of its 5,000 qubit Advantage(TM) quantum computeris significantly faster than classical compute on an intractableclass of optimization problems – 3D spin glasses. The paper alsorepresents the largest programmable quantum simulation reported todate. A collaboration between scientists from D-Wave and BostonUniversity, the paper titled “Quantum critical dynamics in a5,000-qubit programmable spin glass,” was published in thepeer-reviewed journal Nature today and is available here.

“This research marks a significant achievement for quantumtechnology, as it demonstrates a computational advantage overclassical approaches for an intractable class of optimizationproblems,” said Dr. Alan Baratz, CEO of D-Wave. “For those seekingevidence of quantum annealing’s unrivaled performance, this workoffers definitive proof.”

To view the full press release, visit https://ibn.fm/dhs9r

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $0.6183, up 2.1815%, on 1,192,927 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $17.60/$.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced the release of Komodo, its proprietary lidarpoint cloud processor ASIC (Application-Specific IntegratedCircuit) chip. A highly integrated custom SoC, developed by Ceptonin California, Komodo is designed to maximize the technicaladvantages of Cepton’s patented lidar architecture to significantlyimprove point cloud quality while replacing several merchantsilicon devices to dramatically reduce cost. Supported by thecompany’s deep experience in industrializing automotive lidar forvolume production through its flagship ADAS lidar series productionprogram, Komodo successfully achieved production-ready status andis expected to begin shipping in the second quarter of 2023. “Ourgoal is to ultimately offer our customers a customizable black-boxsolution with built-in perception capabilities,” said Dr. Jun Pei,CEO and co-founder of Cepton. “Since 2019, we’ve had a vision ofdeveloping a comprehensive chipset through a series of ASICscovering front-end signal processing, back-end point cloudprocessing and eventually perception capabilities all within thelidar unit. We started with our own signal processor ASIC, Iguana,and now we are proud to unveil Komodo.”

To view the full press release, visit https://ibn.fm/GgcMT

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Wednesday's trading session at $0.4102, up 0.761484%, on 247,212 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.375/$3.20.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

A new study has found that most Canadians who need medical cannabis usually purchase their products from the recreational market instead of the medical system, whichraises safety and health concerns. In Canada, medical marijuana canbe accessed legally through a licensed marijuana seller byindividuals who possess medical authorization, or a prescription.

The study involved 5,744 participants, making it one of the biggestsurveys ever done on how Canadians accessed marijuana for medicalpurposes. It was conducted by a University of Manitoba researcherand completed in collaboration with patient groups SheCannCannabis, Medical Cannabis Canada, McGill University and SantéCannabis. The study determined that more than one-half of thoseinvolved in the survey purchased their cannabis withoutprescriptions. In the years to come, patients who requirecannabis-based medicines may not have to take risks buyingmedicinal products from recreational use shops because entitiessuch as IGC Pharma Inc. (NYSE American: IGC) are working to formulate treatments from THC and othercannabinoids with the aim of alleviating chronic pain and othersymptoms.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Wednesday's trading session at $0.354, up 4.1176%, on 84,834 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.8505.

Recent News

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: BMR) (OTCQB: BTRMF).

A recently conducted survey by Focuseconomics shows that some analysts upped their predictions for the price ofcopper in the final quarter of this year. The Barcelona-basedcompany involved more than 24 investment banks and market researchfirms in its survey.

While the price of copper hit $9,200 per ton after a week of strong gains last week, the consensus predictionfor the average prices of the red metal in Q4 2023 still remainsbelow current levels, at $8,575/ton. The highest forecast, byCommerzbank, stands at $10,050 per ton while the lowest, byEuromonitor, stands at $6,500 per ton.

The price of the red metal is closely tied to the Chinese economybecause the Asian country consumes more than one-half of all coppersupplied globally. New data shows an increase in Chinese exports,which isn’t supported by indicators such as the rapid decline infactory gate prices. However, the growing electrification oftransport and expansion of green energy is likely to give copperextractors such as Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) a positive outlook going forward.

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) is a battery minerals company providing shareholders exposure to the global mega-trend of electrification while being focused on growth through cash-flow, exploration and acquisitions in favorable mining jurisdictions.

The company’s mission is the discovery, acquisition and development of battery metals (namely copper, cobalt, lithium, and graphite) in North America, South America and South Korea. It aims to become a leading low-cost producer of high quality, ethically sourced battery metals from high-grade, low impact mines in stable jurisdictions that are close to major consumer industries.

BMR is headquartered in Vancouver, British Colombia, with a portfolio of projects spanning Canada, the U.S., Chile and South Korea.

Project Portfolio

BMR’s current focus is the restart of its Punitaqui copper mine in Chile, as well as the exploration and development of its cobalt, lithium and graphite assets in North America and South Korea. The company also continues to identify and evaluate new project opportunities in its operating jurisdictions.

Its current portfolio includes:

Chile – Copper

BMR’s 100%-owned Punitaqui copper mine, acquired in March 2021, has the potential to generate an annual EBITDA of up to $50 million at or above a copper price of $4.25/lb. The company’s flagship project, the Punitaqui mine has been the subject of numerous milestones in recent months, including:

  • BMR funded and completed a successful 32,526m resource drill program in 2022. Metallurgical testwork has confirmed the ability to produce excellent copper concentrates from each of the five zones tested, including recoveries ranging from 81% on the low end at Cinabrio Norte up to 96.5% at the Dalmacia deposit.
  • The company in August 2022 reported the results of its first ever NI 43-101-compliant resource estimate for the underground deposits at its Punitaqui copper mining complex of 6.2 million tonnes grading 1.14% Cu in indicated category, along with 3.1 million tonnes grading 0.93% Cu in the inferred category. This resource estimate greatly exceeded management goals.
  • In September 2022, BMR announced the approval by the Chilean Environment Assessment Service for the Environmental Impact Declaration (“DIA”) pertaining to mining at the company’s Cinabrio mine and San Andres deposit. The approval of the DIA allows BMR to move forward with starting mining operations in 2023 and restarting the mill at its Punitaqui copper mining complex soon after.
  • BMR is focused on securing the final funding for the restart of mining and resumption of copper concentrate production at Punitaqui. Once this funding is received, BMR aims to complete mine rehabilitation and development in four to six months, with the ramp up from first production to the full production rate of 20-25 million pounds of copper in concentrate per annum to require a further four to six months.

“From exploration, engineering, community and permitting successes to realizing several non-dilutive means of funding to allow BMR to advance the project, our team looks forward to taking advantage of the renewed positive market sentiment for near term copper pricing and placing ourselves in a strong position to participate in a robust copper sector in 2023,” CEO Martin Kostuik stated in a news release.

Canada – Cobalt/Silver

Between 2016 and April 2018, BMR acquired through claim staking, option, joint venture and direct purchase the largest regional land holding in the historic home of high-grade cobalt-silver veins in Canada known locally as the Cobalt Embayment.

As of February 2023, BMR controlled a land package totaling 9 properties with 4,086 tenements that encompass an area of 84,003.39Ha. The key projects within the land package include McAra, Gowganda, Elk Lake, Fabre and Wilder. From 2017-2022, a total of 412 holes/51,452.34m were drilled on eight projects/20 targets. In addition, a total of 26,709 Line-Km of airborne geophysical surveys & 1,324.84sqkm of LiDAR topography was flown. Follow-up ground geophysical surveys resulted in a total of 37 surveys (514.64 Line-Km) being completed.

Initial NI 43-101 compliant resource defined at McAra (M&I Resource of 1,124,000lbs Co) was detailed in a Technical Report on Cobalt Exploration Assets in Canada dated as of February 5, 2021, with an effective date of October 31, 2020, prepared by SRK Consulting – G Cole PGeo (APGO#1416).

Idaho – Cobalt

BMR holds the Bonanza and East Fork properties located in the historic cobalt-copper-gold Blackbird mining district (Blackbird Mine from 1902-1963 produced 17Mt grading 0.7% Co, 1.4% Cu, and 1 g/t Au) located about 30 kilometers west of Salmon, Idaho. The Bonanza project is immediately adjacent to Jervois Global’s Idaho Cobalt Operations, the United States’ only operating primary cobalt mine. At Bonanza, there are seven mineralized sites within an area over three kilometers wide that extends along a gabbro dyke striking continuously for over six kilometers northward from Noranda’s historic Blackbird Cobalt/Copper mine. The showings on the project are Bonanza Copper Tunnels, Tinker’s Pride, Bonanza Copper #25, Indian Creek, Gray Copper, Blackrock #4 and Papoose #’s 1-4.

From 2018-2021, BMR’s Bonanza Exploration included 550 line-km of airborne magnetics and radiometrics followed up by surface exploration that included rock sampling, soil sampling, channel sampling of historic workings and 3.6km of time domain induced polarization geophysics.

The two properties cover 12 significant cobalt-copper prospects within the known mineralized zone. Both of the BMR Idaho cobalt belt properties host excellent high-grade discovery potential.

South Korea – Graphite

BMR has 100% ownership of the Guemam and Taehwa graphite exploration projects containing high-purity flake graphite deposits. Both assets are past-producing mines with existing local infrastructure and near-term production potential.

Nevada – Lithium

The company’s Amargosa lithium project is in the southern Basin & Range province and central Mojave Desert of Nevada. It is an early-stage exploration opportunity in a favorable region that hosts numerous lithium occurrences, including the Clayton Valley lithium deposit owned by Cypress Development Corp., as well as a major nearby lithium brine mine currently in production called the Silver Peak mine held by Albermarle Corp., one of the world’s largest lithium producers.

Market Opportunity

Near-term forecasts for the copper sector are extremely bullish, with stalwart Wall Street firms such as Goldman Sachs and Bank of America projecting record highs in the coming months. A combination of short-term supply deficits and long-term energy transition demand are expected to buck the downward pressures that have impacted copper prices in recent years.

Goldman in December 2022 forecast a 178K metric ton deficit in the copper market in 2023, causing the firm to raise its 12-month target to $11K/ton and its average price for calendar 2023 to $9,750/ton.

With China likely to continue accelerating efforts to restock depleted inventories in the wake of its COVID-19 reopening and a sustained push toward electrification around the globe placing a strain on supply, BMR is uniquely positioned to capitalize through the anticipated restart of operations at its Punitaqui copper mine.

Management Team

JMartin Kostuik is CEO and a Director of BMR. He brings to the company nearly three decades of diversified experience in the mining industry as a mining engineer and senior executive. Prior to joining BMR, Mr. Kostuik served as president and director of Arizona Gold Corporation and as CEO and director of Rupert Resources Limited. He built a broad base of experience in operations, engineering, exploration and capital projects with various companies including Luna Gold (Equinox), Barrick Gold Corporation, Taseko Mines Limited and DMC Mining Services. Mr. Kostuik earned his B.S. in Mining Engineering from Queen’s University and his M.B.A. from the University of Tennessee.

JMax Satel is the company’s CFO. He has over 18 years of experience as a successful natural resources-focused executive, most recently serving as EVP Corporate Development & Investor Relations for Arrow Exploration Corp., a TSX Venture- and AIM-listed oil & gas company with operations in Colombia and Canada. Prior to joining Arrow, Mr. Satel was principal and co-founder of Bordeaux Capital Inc., a Toronto-based advisory firm focused on the capital needs of companies across the natural resources sector, where he led and executed project financing advisory mandates involving global financial institutions and private equity funds. He earned a Bachelor of Commerce in Finance and Economics from the University of Toronto.

Jacob Willoughby is VP Corporate Development & Strategy for BMR. He brings to the company nearly 17 years of diversified experience in mining capital markets, including over eight years as a mining analyst covering exploration and development companies globally in both precious and base metals. Mr. Willoughby was most recently Vice President of Research and Analyst at Red Cloud Securities in Toronto. He spent two years as President and Director of Aldridge Minerals, a former Canadian based public exploration and development company with assets in Turkey and Papua New Guinea. Mr. Willoughby earned both a B.S. in Geology and a Masters in Business Administration from the University of Windsor.

FingerMotion Inc. (BTRMF), closed Wednesday's trading session at $0.1483, up 4.4918%, on 1,306 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0355/$1.05.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Attorneys recently filed a case appealing the federal government’sdecision to prevent patients using medical cannabis from owningfirearms. The attorneys, who are representing medical marijuanapatients from Florida, are asking the Court of Appeals for theEleventh Circuit to overturn a decision made by the federaldistrict court to dismiss the lawsuit, arguing that the ban is inconsistent with recent Supreme Courtprecedent, in addition to being unconstitutional.

Recently, the Justice Department stated that allowing medical cannabis patients to own guns could undermine the government’s ability to restrictownership by individuals who are addicted to controlled substancessuch as cocaine, meth and fentanyl. The attorneys stated that therespondents attempted to lump the use of legal medical marijuanawith more dangerous and serious substances such as heroin, cocaine,meth and fentanyl, mainly because the respondents lacked historical support for their stance.

The attorneys further note that the argument is based on theassumption that allowing illicit drug users to purchase or possessfirearms will deter the court from siding with them. However, thisignores the fact that the possession of the other substances, savefor marijuana, can constitute a felony that will justify gunrestrictions. Entities such as Advanced Container Technologies Inc. (OTC: ACTX) are likely to follow this case closely since its outcome mayimpact their strategic plans and projections.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.32, even for the day, on 407 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.073/$1.05.

Recent News

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining (NYSE: MUX) (TSX: MUX) owns 51.9% of McEwen Copper, a base metal developer that islooking to solve the copper supply bottleneck by advancing its100%-owned Los Azules Project in the San Juan province ofArgentina. The project hosts a copper-gold-silver deposit whoseultimate depth and lateral extent are yet to be fully determined.“A more recent Preliminary Economic Assessment (‘PEA’) completed in2017 highlights the project’s robust economics. The project’saverage annual production throughout the first 13 years ofoperation is expected to be about 415 million pounds of copper at acash cost of $1.14 per pound, placing it within the lowest costquartile,” a recent article reads. “Tellingly, the cost is muchlower than the prevailing market price of copper, further boostingthe project’s economic prospects. And with the supply bottlenecksand increased demand expected to influence a continuous uptrend,the outlook appears positive. In fact, according to the article inInvesting News, as the need for copper continues to grow, observersbelieve the red metal will become ‘the new precious/industrialmetal – and it’s going to have an importance that’s equivalent tosome of the more attractive metals, such as gold and silver.’”

To view the full article, visit https://ibn.fm/4pVD6

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas and has a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 9th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions in the Americas. In recent months, the company has undertaken strong actions to lower production costs and increase production across its portfolio of gold assets, driving some costs below the industry average. Gold and copper prices are forecast to enter a major uptrend over the next couple years. McEwen Mining is laying the groundwork to capitalize on this opportunity now.

Seldom is management so aligned with investors’ interests with a commitment to the company’s success. CEO Rob McEwen maintains a 17% ownership stake in McEwen Mining and a 15% ownership in McEwen Copper with a combined cost base of roughly $220 million. McEwen founded Goldcorp, where he took the company from a market capitalization of $50 million to over $8 billion, and that same vision led MUX to create McEwen Copper.

For McEwen Mining shareholders, the company’s 68% stake in McEwen Copper is expected to be a gamechanger, turbocharging MUX by creating the world’s next copper unicorn.

McEwen Copper

Most mined copper is currently used in infrastructure, with new critical demand emerging for use in the electrification of transportation and the global energy transformation. The price of copper rose from a low of about $2 per pound two years ago to over $4 per pound today, and strong demand is expected to continue to soar. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global projects annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining is a 68% shareholder in McEwen Copper, holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which was ranked the 9th largest undeveloped copper deposit in the world by Mining Intelligence (2022). Its current copper resources are estimated at 10.2 billion pounds at a grade of 0.48% Cu (Indicated category) and an additional 19.3 billion pounds at a grade of 0.33% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, called Elder Creek.

In a 2017 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 36-year life, but indications are that the project could ultimately become an even larger mine, with a longer life, since in the assessment, only 55% of the known copper resources are to be mined. Numerous drill holes have shown strong copper mineralization extending below the PEA pit bottom. Its average annual production for its first 13 years was pegged at 415 million pounds of copper in the 2017 PEA – enough copper to supply 2.2 million electric vehicles per year.

In August 2022, McEwen Copper closed its non-brokered, private placement offering of $82 million, after securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC. This gives McEwen Copper an imputed value of $258 million, which would give McEwen Mining’s 68% interest a value of approximately $3.70/share. Additional value can be attributed to McEwen Mining’s 1.25% net smelter royalty on both the Los Azules and the Elder Creek projects.

“We completed an $82 million financing for McEwen Copper in a very tough equity market. Rio Tinto, the second largest mining company in the world, through its subsidiary Nuton, now owns 9.7% of McEwen Copper, a result of its investment of $25 million,” Rob McEwen stated in a news release. “Also, Nuton is testing the Los Azules copper mineralization to see if it can accelerate and increase copper recoveries. Another of Rio Tinto’s subsidiaries, Kennecott Exploration, signed an option to earn a 60% interest in McEwen Copper’s other copper project, Elder Creek, by spending $18 million on exploration.”

The Elder Creek project is prospective for porphyry copper and gold mineralization and is well situated in a district hosting several large copper and gold mines, including Marigold, Lone Tree and Phoenix. Kennecott Exploration will be the operator of the exploration program. McEwen Mining holds a 1.25% net smelter return (NSR) royalty on the Elder Creek property.

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project. Publication of an updated PEA on the Los Azules copper project is planned for Q1 2023. In Q2, an IPO is planned, along with MUX completing a secondary offering, assuming no further private placements in the interim. MUX is strategically reducing its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver mines.

McEwen Copper currently has an implied market cap of over $258 million, based on its most recently completed financing. However, when its Los Azules copper project is compared with other recent transactions and market valuations of copper projects in the same region, it appears very undervalued.

MUX’s management believes its ownership stake in McEwen Copper is not currently reflected in the share price of the company. In fact, it is management’s belief that the combined value of its 68% interest in McEwen Copper, plus its gold mines and portfolio of mineral royalties, represents a share value ranging from a low of $8 to a high of $30 per share. Rob McEwen provides a full breakdown of this valuation estimate in a news release detailing the company’s Q3 2022 results.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release. “I am pleased to say that in Q3 our cash cost/oz at Fox fell to $774, our lowest since mid-2018. This is well below the industry average. With our mine operating much more efficiently, our next important area to improve at Fox is the process plant (mill). Specifically, we need to increase the throughput because our mine is now producing more ore than our mill can process. As a result, we have a large surface stockpile of ore equivalent to more than two months of production.”

This ore stockpile contains approximately 10,000 ounces of gold representing a potential source of $12 million in free cash flow.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have, so far, produced in excess of 1,000,000 ounces of gold. Also, it includes the Grey Fox and Stock deposits that have an estimated additional 1,600,000 ounces in reserves and resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, boasting total gold content of over 300 million ounces.

Full year 2023 guidance for The Fox Complex puts production estimates at 45,000 GEOs, 28% of MUX’s total production.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure some 25 miles south of Nevada Gold Mines, a joint venture of Barrick and Newmont. This Cortez-Goldrush complex contains estimated reserves and resources of greater than 50 million gold ounces. Its annual gold production is 1,000,000 ounces.

Gold Bar had been previously mined, between 1991 and 1994, producing 134,000 gold ounces. MUX built a new facility in 2019. The open pit mine was expected to be a large contributor to MUX’s revenue and gold production, however operating challenges arose that reduced gold production and drove cost/oz unacceptably high. Mining activities have shifted recently to a nearby, satellite deposit called Gold Bar South (GBS). Going forward the expectations are higher gold production and lower operating cost/oz as a result of mining a higher ore grade (concentration of gold per ton) and having to move half the amount of material to capture an ounce of gold.

“At Gold Bar, we are looking forward to starting to mine our GBS deposit this quarter,” McEwen said in a November 2022 release. “We are expecting to have a much lower cost/oz than our YTD cost because we will be mining higher grade ore at GBS, with half the strip ratio and no problematic carbonaceous material.”

The Gold Bar Mine will account for approximately 28% of McEwen Mining’s 2023 total attributable production, with guidance pegged at 45,000 GEOs. Most of Gold Bar production in 2023 will be from GBS.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX’s involvement began in 2013 operating it as an open pit, heap leach mine which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. However, due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018. The redevelopment envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material then transition to open pit mining and processing the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to be completed by early 2024.

Mine San José

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine located in Santa Cruz province, Argentina. This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 342 gpt silver and 5.7 gpt gold and a resource grade of 427 gpt silver and 7.0 g/t gold.

“The San José mine, where we have a 49% interest, put in a strong quarter and its exploration is continuing to extend its high-grade veins and discover new veins,” McEwen noted in a news release.

Production guidance for 2023 for MUX’s 49% is 70,000 GEOs, 44% of MUX’s total production. As a minority shareholder in the mine, MUX equity accounts for its investment in San Jose, and it receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks took a beating in the wake of the COVID-19 pandemic. However, that could change, as many analysts are now forecasting a gold bull market in 2023.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – the cost of his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director – America and Mexico Operations. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Wednesday's trading session at $8.74, off by 4.793%, on 566,146 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.81/$10.00.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research, hasbegun development of a novel formulation as a targeted prophylactictreatment. The company is developing the drug formulation inaccordance with its sponsored research agreement with ColumbiaUniversity. Designated as SPC-15, the treatment will be designedfor stress, anxiety and PTSD. Stress-related disorders such asthese are becoming more prevalent, with the World HealthOrganization reporting more than 300 million people struggle withan anxiety disorder. Fortune Business Insights is projecting thatthe global treatment market size for anxiety disorders anddepression will reach $13 billion by 2027. Silo Pharma has a U.S.patent covering SPC-15 as a method for the treatment and preventionof stress-induced affective disorders in females, and studiesindicate that SPC-15 exhibits promise as a potential therapeutictarget for the treatment of cognitive impairment, PTSD andstress-related disorders. “We are advancing our development ofSPC-15 through this formulation and feasibility study investigatingdose strengths and delivery,” said Silo Pharma CEO Eric Weisblum inthe press release. “The SPC-15 treatment protocol predicts levelsof severity or progression of stress-related disorders and theirmetabolomic biomarkers’ response to pharmacological treatments.Based on our own research to date coupled with publishedpreclinical data, we believe SPC-15 could have a profound impact ontreating stress and anxiety disorders including PTSD, we willfurther use this data to help us with our upcoming studies relatedto SPC-14 Alzheimer’s asset.”

To view the full press release, visit https://ibn.fm/xgbQJ

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Wednesday's trading session at $2.24, off by 4.2735%, on 8,391 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.71/$12.225.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore recently announced it is investing $75 million over the nextfour years to set up the Louisiana Strategic Metals Complex(“LSMC”) REE separation and oxide production facility

The facility will cover a footprint of 80,800 square feet and willbe located within the England Airpark Community complex inAlexandria, Louisiana

Ucore expects to produce 7,500 tons per annum of total rare earthoxide (“TREO”) throughput and create 100 family-wage paying jobs

The facility is one of three strategic metals complexes that Ucoreplans to set up across North America as part of efforts to help thecontinent take charge of REEs and other critical elements that arenecessary as the world introduces electric vehicles andelectrification

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the exploration for and separation andscalable production of rare earth elements (“REEs”) in Canada andthe United States, recently announced it is investing $75 millionin capital expenditure (“CapEx”) over the next four years toestablish North America’s first modern technology REE separationand purification facility at the England Airpark Community inAlexandria, Louisiana. The investment will result in theestablishment of the Louisiana Strategic Metals Complex (“LSMC”)REE separation and oxide production facility, whose construction isscheduled to begin this year. Once completed, the facility willcreate 100 family-wage paying jobs (by 2027).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals separation technology company executing anESG-centered plan to establish a comprehensive North Americancritical metals supply chain, is gaining attention thanks to thecommissioning of its demonstration plant in Kingston, Ontario. “Thecompany is positioning itself to fulfill North America’s unmet rareearth element (‘REE’) and rare earth oxide (‘REO’) needs throughcommercial production plants, with the first expected to beoperational by the end of 2024 in Louisiana… Over the last fewyears, Ucore has invested about $10 million in the demonstrationplant and its RapidSX(TM) technology. RapidSX(TM) is a westernizedform of solvent extraction using fewer chemicals, quickerthroughput, less capital expenditure and better operationalexpenditure,” a recent article reads. “Ucore CEO Pat Ryan statedthat the individual rare oxide market is expected to reach $32billion by the decade’s end, with approximately $16 billionbelonging to the ex-China market. Ucore is targeting 20% of thatmarket, with the commercial plant in Louisiana expected to take onone-third of that capacity. Additionally, Ucore plans to engineer asecond and third commercial plant to handle the remaining capacityin the future.”

To view the full article, visit https://ibn.fm/1iIZK

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is engaged in Rare Earth Element (REE) resource development and in commercializing its critical metals separation technology, RapidSX™, for the mining and metals extraction industry. The company is guided by principles of environmental, social and corporate governance (ESG) with a focus on disrupting China’s current dominance of the U.S. REE supply chain.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. It plans to aid in the development, through strategic partnerships, of a North American REE supply chain controlled by the U.S. and its allies.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Wednesday's trading session at $0.965, off by 2.3279%, on 6,192 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.40/$1.15.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

A survey of 742 individuals found that 16% had experienced seriousreactions to gel polish. A warning on this issue was first issued in 2018 by the British Association ofDermatologists following reports of a significant increase inallergic skin reactions linked to the chemicals. Dermatologistsrecently brought the issue to light again, noting the steep rise inthe number of individuals who develop allergies caused by gel nailpolishes seeping into their skin.

The warning notes that the chemicals found in these products maycause a serious, itchy rash to develop on one’s skin as well asloosen the nails. The chemicals in question — methacrylates — aremethacrylic acid derivatives used to make methyl methacrylate andrelated polymers. Methacrylate is usually used as a bone cement for hip and knee implants and indentures and dental prosthesis.

During gel manicures, methacrylate can enter the skin when the UVlamp isn’t used for the suitable period or if the equipment doesn’twork properly. The ultraviolet lamp is usually used to harden thelayers of polish. It seems as if plenty of products that people areusing lately have the potential to trigger allergic reactions. Thisis likely to raise the caseload of patients afflicted by allergicconditions, and it now becomes more urgent for companies such as Aditxt Inc. (NASDAQ: ADTX) engaged in finding ways to retrain the immune system to containautoimmunity to press ahead and commercialize their products.

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.


Aditxt Inc. (NASDAQ: ADTX), closed Wednesday's trading session at $0.86, off by 9.4737%, on 50,909 volume. The average volume for the last 3 months is 50,748 and the stock's 52-week low/high is $0.8304/$28.49.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue lightemergency communication systems, has shipped multiple AutonomousSecurity Robots (“ASRs”) around the country in the past month; thecompany has also shipped numerous blue light emergencycommunication systems. Consequently, the company is reporting areduction in backlog of more than 12%. According to the company,the ASRs were shipped to California, Florida, New York, Washingtonstate and Washington, DC. The robot shipments represented anestimated $258K in annualized revenue. The blue light emergencyshipments represented approximately $417K in revenue.

Knightscope also reported that the Westland Real Estate Group,which operates more than 65 residential communities on the WestCoast, has renewed its contract for a Knightscope K5 ASR to patrola Las Vegas residential community. According to the company, thesecurity robot “performs routine patrol activities and constantlycommunicates with the residential community’s staff. The executivedirector of the Nevada State Apartments Association, Susy Vazquez,was quoted as saying, ‘Wow! Westland, again, is stepping outsidethe box and addressing issues with innovation! I’m fascinated bythe capabilities of this bot and its effectiveness.’”

The next stop for the Knightscope Robot Roadshow is Bossier City,Louisiana; the roadshow is slated to be on location from 10 a.m.–2p.m. CT on April 26–27, 2023. Members of the public, potential andcurrent investors and community leaders are all encouraged to stopby to see for themselves what Knightscope robots can do.Reservations are encouraged but not required.

To schedule a Robot Roadshow time slot, visit https://ibn.fm/akFP3

To view the full press release, visit https://ibn.fm/4Bfro

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Wednesday's trading session at $0.673, off by 3.7334%, on 993,260 volume. The average volume for the last 3 months is 973,354 and the stock's 52-week low/high is $0.575101/$4.75.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG) and DSS Inc. (NYSE American: DSS) have announced plans to distribute to stockholders SHRG commonstock that is beneficially held by DSS. The distribution will bedone through DSS subsidiary, Decentralized Sharing Systems Inc.(“DSSI”). Sharing Services is a diversified direct marketingcompany that is in the process of uplisting to NASDAQ; DSS is amultinational company operating nine business divisions throughstrategic acquisitions and development to build shareholder valuethrough periodic spinoffs. A major shareholder in Sharing Services,DSS is identifying opportunities that will support long-term growthfor SHRG as well as provide long-term benefit to its shareholders.According to the announcement, DSS plans to distributeapproximately 280 million shares, valued at more than $5 million atthe current market value, in a distribution to holders of DSScommon stock. “We look forward to having DSS shareholders as partof our shareholder base through the direct distribution of SHRGshares,” said Sharing Services Global CEO John “JT” Thatch in thepress release. “We also are excited to grow the relationship withDSS and see great potential with them as we expand our distributionnetwork and global footprint to create additional revenue andgrowth.”

To view the full press release, visit https://ibn.fm/MfD5w

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.